Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin add-on to metformin in type 2 diabetes mellitus in Sudan
PACTR202602612886271Unknown
- Sponsor
- Maha Hassan Ahmed
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin add-on to metformin with Placebo add-on to metformin (2 arms). Primary endpoint: HbA1c at Week 16. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202602612886271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202602612886271.